This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status
by Zacks Equity Research
Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
by Zacks Equity Research
Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.
Molecular Templates Surges 50%, Inks Cancer Deal With Takeda
by Zacks Equity Research
Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.
Implied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Pacira Pharmaceuticals (PCRX) stock based on the movements in the options market lately.
United Therapeutics In-Licenses Rights to IPF Candidate
by Zacks Equity Research
United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.
Ironwood Stock Up, Heart Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
by Indrajit Bandyopadhyay
Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.
KemPharm Posts Positive Top-Line Results on KP415 Prodrug
by Zacks Equity Research
KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.
Endocyte (ECYT) Soars: Stock Adds 11.4% in Session
by Zacks Equity Research
Endocyte (ECYT) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
Biogen Begins Phase III Study on Ischemic Stroke Candidate
by Zacks Equity Research
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Pacira (PCRX) Rides High on Robust Exparel Performance
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.
Pacira Pharmaceuticals (PCRX): Moving Average Crossover Alert
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is looking like an interesting pick from a technical perspective
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) encourages investors with better-than-expected earnings and revenues in Q2.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 166.67% and 5.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.
What's in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.
Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?
by Zacks Equity Research
On ACADIA's (ACAD) second-quarter 2018 conference call, investor focus will be on the sales figures of its only marketed drug Nuplazid as well as its pipeline progress.
AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.
Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?
by Zacks Equity Research
We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.
Aerie (AERI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on Rhopressa's initial uptake, and other pipeline and regulatory updates, when Aerie (AERI) reports Q2 results.
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) second-quarter earnings call.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.